Find policies, billing codes, payers, states, and providers
CPT 80306: Presumptive Drug Test by Instrument-Assisted Immunoassay
CPT code 80306 represents instrument-read presumptive drug testing—typically immunoassay screening performed by a laboratory analyst to detect one or more drug classes on a single date. This service is a common first-line laboratory screen used across clinical, occupational, and forensic settings to identify potential drug exposures prior to confirmatory testing. Nationally, presumptive drug testing is a high-volume laboratory service with implications for clinical workflows, laboratory billing, and payer coverage policies.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what CPT code 80306 covers, how it is typically billed and reported in laboratory settings, and where it fits in the testing pathway between initial screen and confirmatory assays. The publication outlines typical sites of service and the service type to clarify clinical context.
The report provides practical benchmarks and policy context relevant to payers and providers: typical utilization scenarios, coding relationships to confirmatory testing, and considerations for documentation and claims processing. Data not available in the input will be identified as such in relevant sections.
Customize your policy alerts
Sign up for cpt 80306 policy alerts
Get alerted when payer policies referencing 80306 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 80306 describes a presumptive drug test or tests performed by a laboratory analyst using instrument-assisted direct optical observation, commonly via immunoassay. The procedure screens for one or more drug classes on a single date using methods that the analyst can read with instruments rather than solely by visual inspection.
Service type: Laboratory diagnostic screening (presumptive drug testing).
Typical site of service: Clinical laboratory or outpatient laboratory facility, including hospital laboratories and independent reference labs where instrument-assisted immunoassay screening is performed.
National Reimbursement Benchmarks
Across national commercial payers, BUCA (average commercial) centers near $30.4 for CPT 80306, offering a useful midpoint for comparison. Blue Cross Blue Shield displays the highest mean at $42.5 and a wide interquartile spread ($44.10 p75 minus $37.80 p25 = $6.30), while Cigna’s mean of $16.4 and Aetna’s mean of $12.6 sit well below BUCA. UnitedHealth Group and Aetna have lower medians ($10.3 and $13.0 respectively) compared with Blue Cross Blue Shield and Cigna.
Dispersion varies meaningfully by payer: Blue Cross Blue Shield’s IQR equals $6.30, the widest among payers, indicating greater regional or contractual variability. UnitedHealth Group shows a tighter IQR of $9.00 (p75 $17.10 minus p25 $7.20 = $9.90) and Cigna’s IQR is $12.40 (p75 $21.40 minus p25 $9.00 = $12.40), while Aetna’s IQR is $6.00 (p75 $16.00 minus p25 $10.00 = $6.00), making Aetna one of the tighter distributions around its median.